Echinacea
Phase 2Small molecule
Echinacea is one of 61 small molecule programs targeting Respiratory tract infection. It is currently in Phase 2.
2
Indications
5
Total Trials
0
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
80 competitors in Respiratory Tract Infection
#DrugCompanyPhaseTrials
1Merrem
BB. Braun Medical Inc.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Tamiflu
CConrado Roberto Hoffmann Filho
Phase 3
Veklury
GileadPhase 2
Quietus
Merck & Co.Phase 2
Nimesulide
Boehringer IngelheimApproved
Rapivab
BBioCryst Pharmaceuticals
Phase 3
Broncho-Vaxom
OOM Pharma SA
Phase 3
Pelubiprofen
Daewon Pharmaceutical Co., Ltd.Phase 3
Rayos
RRoxane Laboratories
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Respiratory tract infection1 trial
Children1 trial
A Trial of Echinacea in Children
Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 3·NCT00029211·600 enrolled
NAC1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Echinacea. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details